By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Aduro Biotech 

740 Heinz Avenue

Berkeley  California  94710  U.S.A.
Phone: 510-848-4400 Fax: n/a


SEARCH JOBS

Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms.


Key Statistics


Email:
Ownership: Public

Web Site: Aduro Biotech
Employees:
Symbol: ADRO
 



Industry
Biotechnology

Segment
Biotechnology





Company News
Partial Clinical Hold Lifted and Enrollment Resumes for Aduro Biotech (ADRO) LADD Clinical Trials 11/21/2016 6:30:24 AM
Why Aduro Biotech (ADRO)'s Clinical Hold Made Investors So Nervous 10/25/2016 6:30:50 AM
FDA Slaps Partial Hold on Bay Area Firm Aduro Biotech (ADRO)'s Cancer Vaccine Trial 10/24/2016 6:19:45 AM
Aduro Biotech (ADRO) Appoints Oncology Expert And Industry Veteran Natalie Sacks, M.D. As Chief Medical Officer 9/7/2016 2:48:20 PM
Aduro Biotech (ADRO) Opens New HQ in the Bay Area, Eventually to House 400 Workers 9/1/2016 8:36:19 PM
10 Biotech Stocks Analysts are Upbeat About in May 5/23/2016 8:24:58 AM
Aduro Biotech (ADRO)'s Stock Craters After Pancreatic Cancer Drug Trial Misses Primary Endpoint 5/16/2016 7:24:21 AM
Investors Hold Their Breath for Data from Aduro Biotech (ADRO), Novartis AG (NVS) 3/11/2016 7:04:49 AM
Aduro Biotech (ADRO) Announces Fourth Quarter And Full Year 2015 Financial Results 3/9/2016 8:08:06 AM
Aduro Biotech (ADRO) To Present At J.P. Morgan Healthcare Conference 1/8/2016 8:01:04 AM
12345678910
//-->